Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

No increase of serum autoantibodies during therapy with recombinant human interferon-β1a in relapsing-remitting multiple sclerosis

(2010) Carlo Colosimo et al.   ACTA NEUROLOGICA SCANDINAVICA

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

(2008) Juan Luís Ruiz-Peña et al.   BMC Neurology

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF

(2008) Alireza Minagar et al.   CURRENT MEDICAL RESEARCH AND OPINION

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

(2008) A. Carrá et al.   EUROPEAN JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study

(2008) S Minden et al.   Multiple Sclerosis Journal

Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon

(2008) I Bosca et al.   Multiple Sclerosis Journal

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Primary headache and multiple sclerosis: preliminary results of a prospective study

(2008) Veronica Villani et al.   NEUROLOGICAL SCIENCES

Quantitative risk-benefit analysis of natalizumab

(2008) J. P. Thompson et al.   NEUROLOGY

Identification and development of new therapeutics for multiple sclerosis

(2008) Ralf A. Linker et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

(2007) E. Le Page et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing–remitting multiple sclerosis

(2007) Nicola De Stefano et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety

(2007) Valentina Zipoli et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES